Abstract Number: 0558 • ACR Convergence 2024
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…Abstract Number: 0482 • ACR Convergence 2024
Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis
Background/Purpose: CV disease is leading cause of morbidity and mortality in RA, largely due to endothelial dysfunction.1. Endothelial function is barometer of total cardiovascular risk while…Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…Abstract Number: 0563 • ACR Convergence 2024
Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort
Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…Abstract Number: 0573 • ACR Convergence 2024
Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data
Background/Purpose: A large proportion of patients with ankylosing spondylitis (AS) are considered difficult to treat (D2T).The study aimed to compare baseline characteristics, extra-articular manifestations (EAM),…Abstract Number: 0580 • ACR Convergence 2024
Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…Abstract Number: 0570 • ACR Convergence 2024
Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…Abstract Number: 0544 • ACR Convergence 2024
A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort
Background/Purpose: Axial spondyloarthritis (axSpA) frequently leads to reduced spinal and hip mobility, though evidence pertains mostly to patients with longstanding disease and radiographic damage. More…Abstract Number: 0572 • ACR Convergence 2024
Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects
Background/Purpose: Recent evidence suggests lower response rates to tumor necrosis factor inhibitors (TNFi) among women with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is a paucity…Abstract Number: 0556 • ACR Convergence 2024
Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis
Background/Purpose: Valve degeneration is prevalent in Spondylarthritis (SpA) patients according to descriptive studies, but it is also common in general population. Disease burden may be…Abstract Number: 0543 • ACR Convergence 2024
Impact of Peripheral Manifestations on Function, Health, and Work Productivity in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Background/Purpose: Peripheral musculoskeletal manifestations can occur either concomitantly with axial disease or independently in patients with spondyloarthritis (SpA). However, it is not known whether the…Abstract Number: 0473 • ACR Convergence 2024
Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology
Background/Purpose: The increasing use of Immune Check-Point Inhibitors (ICIs) to treat malignancy focused attention on immune-related adverse events (irAEs). ICIs-induced arthritis is the most common…Abstract Number: 0552 • ACR Convergence 2024
Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate immune T cells that are located at the mucosal barriers. They play a role in mucosal defense,…Abstract Number: 0583 • ACR Convergence 2024
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
- « Previous Page
- 1
- …
- 265
- 266
- 267
- 268
- 269
- …
- 2607
- Next Page »
